Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

    ... ⩽10 g/dl, low transfusion burden, and serum erythropoietin ⩽500 mU/ml. Patients were randomized 2:1 to receive 24 ... of 9.3 (Q1:8.8, Q3:9.7) g/dl and median baseline serum erythropoietin of 69 (Q1:36, Q3:158) mU/ml. Transfusion incidence from weeks ...

    Research Article last updated 07/11/2017 - 10:16am.

  2. MEDALIST Trial

    ... ESA regimen must have been either recombinant human erythropoietin (rHu EPO) > 40,000 IU/wk for at least 8 doses or ... low chance of response to ESA base on endogenous serum erythropoietin level > 200 U/L for subjects not previously treated with ESAs ...

    Clinical Trial last updated 02/22/2017 - 11:42am.

  3. Treatment of low-risk myelodysplastic syndromes

    ... is performed on the basis of IPSS-R, endogenous erythropoietin levels, and transfusion independence . Doses and ...

    Research Article last updated 01/26/2017 - 10:42am.

  4. MDS Follows Two Misdiagnoses

    ... as relatively low risk. I have been treated with erythropoietin (Procrit®), G-CSF, (Neupogen®), azacitidine , ...

    Patient Chronicle last updated 12/27/2016 - 7:23am.

  5. Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromes

    ... the disease. Here we show effects of recombinant human erythropoietin (rHuEPO) on T cell (CD4+, CD8+ and CD4+CD25+) number ...

    Research Article last updated 12/09/2016 - 3:05pm.

  6. A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

    ... with the exception that growth factors (G-CSF, erythropoietin , and TPO) and transfusions are allowed before and during the ...

    Clinical Trial last updated 11/29/2016 - 8:29am.

  7. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    ... were observed in patients with lower baseline endogenous erythropoietin ≤ 500 mU/mL (34.0% v 15.5% for > 500 mU/mL). At week 12, ...

    Research Article last updated 07/18/2016 - 10:30am.

  8. Efficacy and safety of darbepoetin alpha in patients with myelodysplastic syndromes: a systematic review and meta-analysis

    ... response duration range was 12-51+ months. Patients with erythropoietin (EPO) <100 iu/l had 35% [95% confidence interval (CI): ...

    Research Article last updated 06/23/2016 - 9:14am.

  9. Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.

    ... of treatment with deferasirox combined with erythropoietin vs. erythropoietin alone on erythropoiesis in patients with low- and ...

    Clinical Trial last updated 04/27/2016 - 12:52pm.

  10. Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

    ... must not be receiving growth factors, except for erythropoietin . Subjects with a "currently active" second malignancy, ...

    Clinical Trial last updated 06/13/2016 - 3:24pm.